Etomidate puts patients at risk of adrenal crisisBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e7444 (Published 06 November 2012) Cite this as: BMJ 2012;345:e7444
- 1St Mary’s Hospital, Imperial College Healthcare NHS Trust, London W2 6HP, UK
- 2Central Middlesex Hospital, North West London Hospitals NHS Trust, London
Wass and Arlt do not mention that certain anaesthetic techniques may increase patients’ risk of adrenal crisis.1
Because the carboxylated imidazole induction agent etomidate causes fewer haemodynamic effects than other intravenous agents,2 it may be preferred for the sickest patients undergoing surgery.
Its suppressive effects on the adrenocortical axis (by inhibiting 11 β-hydroxylase and 17 α-hydroxylase) have been known for 30 years, and ended its use for sedation in critical care units.3
Patients receiving etomidate should be closely monitored for postoperative adrenal crisis, and careful consideration given to hydrocortisone administration.
Good communication between anaesthetists, surgeons, and others caring for such patients is paramount.
Cite this as: BMJ 2012;345:e7444
Competing interests: None declared.